WHO (World Health Organization) Toxicity Criteria by Grade

Size: px
Start display at page:

Download "WHO (World Health Organization) Toxicity Criteria by Grade"

Transcription

1 WHO (World Health Organization) Toxicity Criteria by Grade 化學治療以 WHO Toxicity Criteria 為主放射治療有分急性與慢性副作用以 RTOG Toxicity Criteria 為主 WHO Toxicity Criteria Category Toxicity Grade0 Grade1 Grade2 Grade3 Grade4 Haematology WBC (x103/l) < 1.0 Haematology Platelets (x103/l) WNL normal < 25.0 Haematology Haemoglobin (g/dl) WNL normal < 6.5 Haematology Granulocytes/ Bands (x103/l) < 0.5 Haematology Lymphocytes (x103/l) < 0.5 gross, 1-2 gross, 3-4 massive, > 4 Haematology Haemorrhage none mild, no units units units transfusion transfusion per transfusion per per episode episode episode Coagulatio Fibrinogen WNL x N x N x N < 0.25 x N Coagulatio Prothrombin x WNL x N time(quick) N x N > 2.00 x N Coagulatio Partial thrombo x WNL x N plastin time N x N > 3.00 x N Hyperglycaemia > 500 or < ketoacidosis Hypoglycaemia > < 30 Amylase WNL < 1.5 x N x N N > 5.0 x N Hypercalcaemia < Hypocalcaemia > Hypomagnesaemia > Gastrointestinal Nausea none able to eat intake no significant

2 reasonable intake significantly decreased but can eat Gastrointestinal Vomiting none 1 episode in 24 hrs 2-5 episodes in 24 hrs Gastrointestinal Diarrhoea Gastrointestinal Stomatitis Kidney, Kidney, Kidney, Bilirubin (N = 17 µmol/l) Transaminase (SGOT, SGPT) Alk Phos or 5 nucleotidase - clinical none none increase of 2-3 stools / day over pre-rx painless ulcers, erythema, or mild soreness intake increase of 4 - increase of 7-6 stools / day, 9 stools / day, or nocturnal or stools, or incontinence, moderate or severe cramping cramping painful painful erythema, erythema, oedema, or oedema, or ulcers and ulcers but can cannot eat eat solids solids > 10 episodes in 24 hrs or 6-10 episodes requiring in 24 hrs paren- teral support increase of > 10 stools / day or grossly bloody diarrhoea, or need for parenteral support requires parenteral or enteral support for alimentation WNL < 1.5 x N x N > 3.0 x N WNL 2.5 x N x N x N > 20.0 x N WNL < 2.5 x N x N x N > 20.0 x N No from baseline precoma hepatic coma Creatinine WNL < 1.5 x N x N x N > 6.0 x N 1 (+) or < 0.3 g% Proteinuria No or 3 g/l Haematuria Negative microscopic only 2-3 (+) or g% or 3-10 g/l 4 (+) or > 1.0 nephrotic g% or > 10g/L syndrome gross and clots requires transgross, no clots fusion or no Rx needed irrigation cystectomy Kidney, Weight gain/ loss < 5.0 % % % 20.00%

3 Pulmonary Pulmonary with dyspnoea on dyspnoea at dyspnoea at abnormal- ity in significant normal level of rest PFTs exertion activity requires moni- Cardiac recurrent or toring; or Cardiac persistent, no requires hypo- tension, none transient, requiring arrhythmias therapy treatment or ventricular no therapy required tachycardia or fibrillation Cardiac Cardiac function none decline of resting decline of resting mild CHF, ejection severe of ejection fraction by responsive to fraction by refractory CHF less than 20 % of therapy more than 20 baseline value % of baseline value Cardiac Cardiac ischaemia none ST and T angina without acute non-specific T- wave s evidence of myocardial wave flattening suggesting infraction infarction ischaemia Cardiac pericarditis symptomatic tamponade; asymptomatic Cardiac- (rub, chest effusion; drainage none effusion, no pericardial pain, ECG drainage urgently itervention required s) required required Cardiac Hypertension recurrent or persistent increase by transient increase greater than by greater than mm HG mm Hg (D) or to > requires hypertensive (D) or to > 150 / 100 if therapy crisis 150 / 100 if previously WNL. previously No treatment WNL. No required. treatment required. Cardiac Hypotension s requiring requires fluid requires requires no therapy (incl- replacement therapy and therapy and

4 uding transient orthostatic hypoor other therapy but hospitalisation; hospitalisresolves within ation for > 48 tension) not 48 hours of hrs after hospitalisation stopping the agent stopping the agent mild or severe Neurologic Neuro: sensory moderate objective mild paraesthesias; objective sensory loss or loss of deep tendon sensory loss paraesthesias reflexes moderate that interfere paraesthesias with function Neurologic Neuro: motor mild objective objektive weakness subjective weak- weak- ness without ness; no objective with paralysis significant findings impairment of impair- ment function of function severe somnolence, (>50 % Neurologic Neuro: cortical none moderate waking hours), mild somnolence coma, seizures, somnolence or agitation, or agitation toxic psychosis agitation confusion, disorientation or hallucinations intention Neurologic Neuro: cerebellar none tremor, slight dysmetria, locomotor cerebellar incoordination, slurred ataxia necrosis dysdiadochokinesia speech, nystagmus Neurologic Neuro: mood moderate mild anxiety or severe anxiety suicidal no anxiety or depression or depression ideation depression Neurologic Neuro: headache none mild moderate or unrelenting severe but and severe transient Neurologic Neuro: mild constipation moderate severe ileus > 96 hrs

5 Neurologic Neuro: hearing hearing loss interfering with function deafness not hearing loss on tinnitus but correctable correctable audiometry only with hearing aid Neurologic Neuro: vision symptomatic subtotal loss of blindness vision Pain Pain none mild moderate severe reg. narcotics scattered Skin Skin macular or generalised papular scattered macular symptomatic exfoliative eruption or ot papular eruption macular, dermatitis or erythema with or erythema that is papular or ulcerating pruritus or asymptomatic vesicular dermatitis other eruption associated symptoms Alopecia Alopecia no loss mild hair loss pronounced or total hair loss Allergy Allergy none serum urticaria, drug sickness, transient rash, drug fever 38oC bronchospasm fever < 38oC (100.4oF), anaphylaxis requiring (100.4oF) mild parenteral bronchospasm medication pain and Local Local none pain swelling with plastic surgery ulceration inflammation indicated or phlebitis > 40.0oC (>104oF) for Fever of > 40.0oC > Fever of unknown o C oC more than 24 unknown none 104.0oF for origin 98.7o o F oF hrs or origin less than 24hrs accompanied by hypotension Infection Infection none mild moderate severe life-threatening Additional Asthenia Analogous

6 Additional Additional Additional to Karnofsky index (WHO grading) Analogous Chills to fever analogous Peripheral oedema to weight gain analogous Anorexia to weight loss

Azathioprine toxicity criteria and severity descriptors for the listing of biological agents for rheumatoid arthritis on the PBS

Azathioprine toxicity criteria and severity descriptors for the listing of biological agents for rheumatoid arthritis on the PBS Azathioprine toxicity criteria and severity descriptors for the listing of biological agents for rheumatoid arthritis on the PBS Only valid for adult patients Azathioprine must be at a dose of at least

More information

TABLE FOR GRADING THE SEVERITY OF ADVERSE EVENTS

TABLE FOR GRADING THE SEVERITY OF ADVERSE EVENTS TABLE FOR GRADING THE SEVERITY OF ADVERSE EVENTS Green AEs managed by DTUs REMARK Red Patient referral to provincial hospitals for AE management Note: In the case of patients with events at grade of severity

More information

T: N: M: EORTC SYSTEMIC THERAPY CHECKLIST. Protocol number: SeqID. Copyright EORTC August 2007 COMPARATIVE PERFORMANCE STATUS TABLE

T: N: M: EORTC SYSTEMIC THERAPY CHECKLIST. Protocol number: SeqID. Copyright EORTC August 2007 COMPARATIVE PERFORMANCE STATUS TABLE EORTC SYSTEMIC THERAPY CHECKLIST Copyright EORTC August 2007 (Stick the patient s identification label here) Protocol number: SeqID. T: N: M: WHO / ECOG 0 Normal activity. 1 Symptoms but ambulatory. 2

More information

Antiemetic protocol for low-moderately emetogenic chemotherapy (see SCNAUSEA)

Antiemetic protocol for low-moderately emetogenic chemotherapy (see SCNAUSEA) BC Cancer Protocol Summary for First Line Treatment of Locally Advanced Metastatic Pancreatic Cancer with Gemcitabine Protocol Code Tumour Group Contact Physician GIPGEMABR Gastrointestinal GI Systemic

More information

Breast Pathway Group EC x 4 Docetaxel x 4: Epirubicin & Cyclophosphamide followed by Docetaxel in Early Breast Cancer

Breast Pathway Group EC x 4 Docetaxel x 4: Epirubicin & Cyclophosphamide followed by Docetaxel in Early Breast Cancer Breast Pathway Group EC x 4 Docetaxel x 4: Epirubicin & Cyclophosphamide followed by Docetaxel in Early Breast Indication: Neoadjuvant therapy for high risk and fit breast cancer patients suitable for

More information

Breast Pathway Group TC (Docetaxel / Cyclophosphamide) in Early Breast Cancer

Breast Pathway Group TC (Docetaxel / Cyclophosphamide) in Early Breast Cancer Breast Pathway Group TC (Docetaxel / Cyclophosphamide) in Early Breast Cancer Indication: Neoadjuvant or adjuvant treatment for patients in whom anthracyclines are contraindicated or inappropriate Regimen

More information

BC Cancer Protocol Summary for Therapy of Adjuvant Breast Cancer using Capecitabine

BC Cancer Protocol Summary for Therapy of Adjuvant Breast Cancer using Capecitabine BC Cancer Protocol Summary for Therapy of Adjuvant Breast Cancer using Capecitabine Protocol Code Tumour Group Contact Physician BRAJCAP Breast Dr. Stephen Chia ELIGIBILITY: Adjuvant breast cancer therapy

More information

MabThera. SC. The wait is over. MabThera delivered in just 5 minutes. SC= subcutaneous injection

MabThera. SC. The wait is over. MabThera delivered in just 5 minutes. SC= subcutaneous injection MabThera SC. The wait is over. MabThera delivered in just 5 minutes Abbreviated Prescribing Information MabThera 1400 mg solution for subcutaneous (SC) injection (Rituximab) Indications: Indicated in adults

More information

TIP Paclitaxel, Ifosfamide and Cisplatin

TIP Paclitaxel, Ifosfamide and Cisplatin Systemic Anti Cancer Treatment Protocol TIP Paclitaxel, Ifosfamide and Cisplatin PROTOCOL REF: MPHATIPGC (Version No: 1.0) Approved for use in: Second line treatment of germ cell tumours Dosage: Drug Dosage

More information

Carboplatin / Liposomal Doxorubicin CARBO/CAELYX Gynaecological Cancer

Carboplatin / Liposomal Doxorubicin CARBO/CAELYX Gynaecological Cancer Systemic Anti Cancer Treatment Protocol Carboplatin / CARBO/CAELYX Gynaecological Cancer PROCTOCOL REF: MPHAGYNCCX (Version No: 1.0) Approved for use in: Advanced ovarian cancer in women who have progressed

More information

Breast Pathway Group Docetaxel in Advanced Breast Cancer

Breast Pathway Group Docetaxel in Advanced Breast Cancer Breast Pathway Group Docetaxel in Advanced Breast Cancer Indication: First-line palliative treatment, with or without trastuzumab, for advanced breast cancer in patients for whom an anthracycline is not

More information

Nausicalm solution for injection is a clear colourless solution, presented in 1 ml ampoules.

Nausicalm solution for injection is a clear colourless solution, presented in 1 ml ampoules. Nausicalm Cyclizine lactate 50 mg/ml solution for injection Presentation Nausicalm solution for injection is a clear colourless solution, presented in 1 ml ampoules. Uses Actions Cyclizine is a piperazine

More information

Lung Pathway Group Docetaxel & Carboplatin in Non- Small Cell Lung Cancer (NSCLC)

Lung Pathway Group Docetaxel & Carboplatin in Non- Small Cell Lung Cancer (NSCLC) Lung Pathway Group Docetaxel & Carboplatin in Non- Small Cell Lung Cancer (NSCLC) Indication: First line palliative therapy for previously untreated Stage IIIB or IV NSCLC patients Regimen details: Docetaxel

More information

DERBY-BURTON CANCER NETWORK CONTROLLED DOC NO:

DERBY-BURTON CANCER NETWORK CONTROLLED DOC NO: OBINUTUZUMAB+CHLORAMBUCIL Regimen RDH; Day 1 and 2 Dose to be given on Ward Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community

More information

Coping. with. Chemotherapy

Coping. with. Chemotherapy Coping with Chemotherapy A handbook for cancer patients who are receiving drug treatment for cancer Introduction Chemotherapy is an important tool in the treatment of cancer. It is used in several ways,

More information

Bridges Family Wellness PC. New Patient Intake. Bridges Family Wellness Intake Form SE Lake Rd, Suite 102 Milwaukie, OR

Bridges Family Wellness PC. New Patient Intake. Bridges Family Wellness Intake Form SE Lake Rd, Suite 102 Milwaukie, OR New Patient Intake Bridges Family Wellness Intake Form Full Name: * What is your birthdate? MM/DD/YYYY * What is your gender identity? * Home address: * Cell Phone * Other Phone number(s): Emergency Contact

More information

BCCA Protocol Summary for Therapy of Metastatic Breast Cancer using Capecitabine

BCCA Protocol Summary for Therapy of Metastatic Breast Cancer using Capecitabine BCCA Protocol Summary for Therapy of Metastatic Breast Cancer using Capecitabine Protocol Code Tumour Group Contact Physician BRAVCAP Breast Dr. Susan Ellard ELIGIBILITY: First line treatment of metastatic

More information

BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer Using Trastuzumab (HERCEPTIN) and Capecitabine

BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer Using Trastuzumab (HERCEPTIN) and Capecitabine BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer Using Trastuzumab (HERCEPTIN) and Capecitabine Protocol Code Tumour Group Contact Physician UBRAVTCAP Breast Dr. Stephen Chia ELIGIBILITY:

More information

Breast Pathway Group Bevacizumab & Paclitaxel in Advanced Breast Cancer

Breast Pathway Group Bevacizumab & Paclitaxel in Advanced Breast Cancer Breast Pathway Group Bevacizumab & Paclitaxel in Advanced Breast Cancer Indication: First-line or second-line treatment of triple negative advanced breast cancer National Cancer Drug Fund criteria: Advanced

More information

Example Clinician Educational Material for Providers of Immune Effector Cellular Therapy

Example Clinician Educational Material for Providers of Immune Effector Cellular Therapy Example Clinician Educational Material for Providers of Immune Effector Cellular Therapy Disclaimer: This example is just one of many potential examples of clinician education material that can be provided

More information

PREMEDICATIONS: Antiemetic protocol for highly emetogenic chemotherapy. May not need any antiemetic with

PREMEDICATIONS: Antiemetic protocol for highly emetogenic chemotherapy. May not need any antiemetic with BCCA Protocol Summary for Palliative Therapy of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma, or Anal Squamous Cell Carcinoma using

More information

MEDICINE SUMMARY. Atomoxetine Hydrochloride Layer 1 of 8 ALL REPORT DATES. Tachycardia. Supraventricular tachycardia. Palpitations.

MEDICINE SUMMARY. Atomoxetine Hydrochloride Layer 1 of 8 ALL REPORT DATES. Tachycardia. Supraventricular tachycardia. Palpitations. Atomoxetine Hydrochloride Layer 1 of 8 ALL REPORT DATES Causality Unclear Exclud Total Sole Suspected - Cases Including Medicine - Occurrences of Medicine - Reactions Related to Medicine Blood and lymphatic

More information

Cycle 1 PERTuzumab (day 1) and trastuzumab (day 2) loading doses: Drug Dose BC Cancer Administration Guideline

Cycle 1 PERTuzumab (day 1) and trastuzumab (day 2) loading doses: Drug Dose BC Cancer Administration Guideline BC Cancer Protocol Summary for Palliative Therapy for Metastatic Breast Cancer Using PERTuzumab, Trastuzumab (HERCEPTIN), and PACLItaxel as First-Line Treatment for Advanced Breast Cancer Protocol Code:

More information

INSTRUCTIONS: 1. Use codetable on page 1 for modifications / termination reasons

INSTRUCTIONS: 1. Use codetable on page 1 for modifications / termination reasons Radiation Therapy Oncology Group Phase III Head & Neck Cancer Treatment Summary Form AMENDED DATA YES INSTRUCTIONS: 1 Use codetable on page 1 for modifications / termination reasons SUMMARY OF SYSTEMIC

More information

Obinutuzumab+Bendamustine followed by Obinutuzumab Maintenance Burton in-patient Derby in-patient Burton day-case Derby day-case

Obinutuzumab+Bendamustine followed by Obinutuzumab Maintenance Burton in-patient Derby in-patient Burton day-case Derby day-case Obinutuzumab+Bendamustine followed by Obinutuzumab Maintenance Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Available

More information

Headache Follow-up Visit Form

Headache Follow-up Visit Form !1 Headache Follow-up Visit Form We will be unable to see you unless this form is completely filled out. We appreciate your thoroughness. Name DOB Age Today s Date Referring doctor: Primary doctor: Neurologist:

More information

Drugs used in obstetrics

Drugs used in obstetrics Drugs used in obstetrics Drugs used in obstetrics Drugs may be used to modify uterine contractions. These include oxytocic drugs used to stimulate uterine contractions both in induction of labour and to

More information

Appendix 4. TOXICITY SCALE (CTC-NCIC CRITERIA) Recommendations for Grading of Acute and Subacute Toxicity, Version Dec 1994 (revised)

Appendix 4. TOXICITY SCALE (CTC-NCIC CRITERIA) Recommendations for Grading of Acute and Subacute Toxicity, Version Dec 1994 (revised) AL LER Allergy transient rash, fever < 38 C, 100.4 F AL OTH other * ALLERGY urticaria, fever = 38 C, 100.4 F, mild bronchospasm serum sickness, bronchospasm, parenteral meds anaphylaxis Fever felt to be

More information

Liposomal Doxorubicin (CAELYX) Gynaecological Cancer

Liposomal Doxorubicin (CAELYX) Gynaecological Cancer Systemic Anti Cancer Treatment Protocol Liposomal Doxorubicin (CAELYX) Gynaecological Cancer PROCTOCOL REF: OPHAGYNCAE (Version No: 1.0) Approved for use in: Advanced ovarian cancer second/third line treatment

More information

BCCA Protocol Summary for Curative Combined Modality Therapy for Carcinoma of the Anal Canal Using Mitomycin, Capecitabine and Radiation Therapy

BCCA Protocol Summary for Curative Combined Modality Therapy for Carcinoma of the Anal Canal Using Mitomycin, Capecitabine and Radiation Therapy BCCA Protocol Summary for Curative Combined Modality Therapy for Carcinoma of the Anal Canal Using Mitomycin, and Radiation Therapy Protocol Code: Tumour Group: Contact Physician: GICART Gastrointestinal

More information

BCCA Protocol Summary for Adjuvant Therapy of Colon Cancer using

BCCA Protocol Summary for Adjuvant Therapy of Colon Cancer using BCCA Protocol Summary for Adjuvant Therapy of Colon Cancer using Capecitabine Protocol Code Tumour Group Contact Physician GIAJCAP Gastrointestinal GI Systemic Therapy ELIGIBILITY: Resected Stage III or

More information

DEEP BRAIN STIMULATION SURGICAL CANDIDACY EVALUATION FORM

DEEP BRAIN STIMULATION SURGICAL CANDIDACY EVALUATION FORM Name: MR#: Date: DEEP BRAIN STIMULATION SURGICAL CANDIDACY EVALUATION FORM Referring Physician s Name: Primary Care Provider s Name: 1. What was/were your first movement disorder symptoms? What did you

More information

BCCA Protocol Summary for Combined Modality Adjuvant Therapy for High Risk Rectal Carcinoma using Capecitabine and Radiation Therapy

BCCA Protocol Summary for Combined Modality Adjuvant Therapy for High Risk Rectal Carcinoma using Capecitabine and Radiation Therapy BCCA Protocol Summary for Combined Modality Adjuvant Therapy for High Risk Rectal Carcinoma using Capecitabine and Radiation Therapy Protocol Code: Tumour Group: Contact Physician: GIRCRT Gastrointestinal

More information

BC Cancer Protocol Summary for Adjuvant Therapy of Colon Cancer using Fluorouracil Injection and Infusion and Leucovorin Infusion

BC Cancer Protocol Summary for Adjuvant Therapy of Colon Cancer using Fluorouracil Injection and Infusion and Leucovorin Infusion BC Cancer Protocol Summary for Adjuvant Therapy of Colon Cancer using Fluorouracil Injection and Infusion and Leucovorin Infusion Protocol Code: Tumour Group: Contact Physician: GIAJFL Gastrointestinal

More information

Carboplatin / Gemcitabine Gynaecological Cancer

Carboplatin / Gemcitabine Gynaecological Cancer Systemic Anti Cancer Treatment Protocol Carboplatin / Gemcitabine Gynaecological Cancer PROCTOCOL REF: MPHAGYNCAG (Version No: 1.0) Approved for use in: Recurrent/metastatic endometrial carcinoma Previously

More information

BCCA Protocol Summary for Second line Treatment of Metastatic or Unresectable Pancreatic Adenocarcinoma Using Capecitabine

BCCA Protocol Summary for Second line Treatment of Metastatic or Unresectable Pancreatic Adenocarcinoma Using Capecitabine BCCA Protocol Summary for Second line Treatment of Metastatic or Unresectable Pancreatic Adenocarcinoma Using Capecitabine Protocol Code Tumour Group Contact Physician GIPAVCAP Gastrointestinal GI Systemic

More information

J. Van Lier Ribbink, M.D., F.A.C.S. Center for Endocrine and Pancreas Surgery at Honor Health

J. Van Lier Ribbink, M.D., F.A.C.S. Center for Endocrine and Pancreas Surgery at Honor Health J. Van Lier Ribbink, M.D., F.A.C.S. Center for Endocrine and Pancreas Surgery at Honor Health Patient Clinical Information Questionnaire 1.0 Date of Questionnaire Completion; / / 2.0 Patient Data 2.1 Name:

More information

DERBY-BURTON LOCAL CANCER NETWORK FILENAME Peruse.DOC CONTROLLED DOC NO: CCPG R29

DERBY-BURTON LOCAL CANCER NETWORK FILENAME Peruse.DOC CONTROLLED DOC NO: CCPG R29 Pertuzumab + Trastuzumab + Docetaxel (Peruse study) A Multicenter, open-label, single arm study of Pertuzumab in combination with Trastuzumab and a Taxane in first-line treatment of patients with HER2-positive

More information

Case Series Drug Analysis Print Name: Vaxigrip, Fluarix, Inflexal V og Influenzacvaccine 01Sep Oct2014

Case Series Drug Analysis Print Name: Vaxigrip, Fluarix, Inflexal V og Influenzacvaccine 01Sep Oct2014 - 16Oct2014 Report Run Date: 20-Oct-2014 Data Lock Date: 16-Oct-2014 19:00:06 Earliest Reaction Date: 28-Oct-2009 MedDRA Version: MedDRA 17.0 Vaxigrip, Fluarix, Inflexal V og Influenzacvaccine : Alle cases

More information

Nilotinib AEs (adverse events) in CML population:

Nilotinib AEs (adverse events) in CML population: Nilotinib AEs (adverse events) in CML population: The percentages below were taken from a randomized trial of nilotinib 300mg BID in newly diagnosed Ph+ CML patients (N=279) taken from the Tasigna 2017

More information

Elements for a Public Summary

Elements for a Public Summary VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Alzheimer's disease is the most common form of dementia, a general term for memory loss and other intellectual abilities serious

More information

Patient Name: Date: Address: Primary Care Physician: Online Website On TV In print On the radio

Patient Name: Date:  Address: Primary Care Physician: Online Website On TV In print On the radio 927 W. Myrtle St. Boise, ID 83702 (208) 947-0100 NEW PATIENT INTAKE Patient Name: Date: Email Address: Primary Care Physician: How did you hear about AVT? (Please mark all that apply) Online Website On

More information

DRUG EXTRAVASATION. Vesicants. Irritants

DRUG EXTRAVASATION. Vesicants. Irritants DRUG EXTRAVASATION Vesicants Irritants Vesicants Antineoplastic drugs Amsacrine Dactinomycin Daunorubicin Docetaxel (rare) Doxorubicin Epirubicin Idarubicin Mechlorethamine Mitomycin Oxaliplatin (rare)

More information

Please describe, in detail, when the symptoms began:

Please describe, in detail, when the symptoms began: 161 East Mallard Drive, Suite 130, Boise, ID 83706 (208) 947-0100 New Patient Intake Patient Name: Primary Care Physician: Date: Email address: How did you hear about AVT (mark all that apply) Online On

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Block GA, Bushinsky DA, Cunningham J, et al. Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism:

More information

Essential Shared Care Agreement Drugs for Dementia

Essential Shared Care Agreement Drugs for Dementia E098 Essential Shared Care Agreement Drugs for Dementia Please complete the following details: Patient s name, address, date of birth Consultant s contact details (p.3) And send One copy to: 1. the patient

More information

HD CLINIC MEDICAL HISTORY FORM

HD CLINIC MEDICAL HISTORY FORM HD CLINIC MEDICAL HISTORY FORM Welcome to the HDSA Center of Excellence HD Clinic. Please take a few moments to answer the questions below as best as you can. If you need assistance, a caregiver/companion

More information

DIVISION OF CARDIOLOGY

DIVISION OF CARDIOLOGY Name: Date of Birth: / / Home Phone #: Cell Phone #: Work Phone #: Fax #: Address: City: State: Zip: Primary Care Physician: Office Address: Work #: Fax #: Referring Physician (if different): Office Address:

More information

Bilaga 5. Biverkningsrapporter för metylfenidat

Bilaga 5. Biverkningsrapporter för metylfenidat Bilaga 5. Biverkningsrapporter för metylfenidat Totalt har 79 rapporter inkommit under perioden 20060101-20081013 varav 71 bedömts ha minst möjligt samband. I dessa 71 rapporter förekom 94 reaktioner,

More information

Core Safety Profile. Pharmaceutical form(s)/strength: Capsules, 0.5 mg AT/H/PSUR/0028/001 Date of FAR:

Core Safety Profile. Pharmaceutical form(s)/strength: Capsules, 0.5 mg AT/H/PSUR/0028/001 Date of FAR: Core Safety Profile Active substance: Anagrelide hydrochloride Pharmaceutical form(s)/strength: Capsules, 0.5 mg P-RMS: AT/H/PSUR/0028/001 Date of FAR: 02.08.2010 4.3 Contraindications Hypersensitivity

More information

GLOSSARY OF MEDICAL TERMS IN LAY LANGUAGE

GLOSSARY OF MEDICAL TERMS IN LAY LANGUAGE GLOSSARY OF MEDICAL TERMS IN LAY LANGUAGE The CSM Working Group on Patient Information recognises that users may not be familiar with the terms used in patient information leaflets to describe unwanted

More information

EXCLUSIONS: Suspected dihydropyrimidine dehydrogenase (DPD) deficiency (see Precautions)

EXCLUSIONS: Suspected dihydropyrimidine dehydrogenase (DPD) deficiency (see Precautions) BC Cancer Protocol Summary for Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Fluorouracil Injection and Infusion and Leucovorin Infusion Protocol Code: Tumour Group: Contact

More information

PATIENT HEALTH QUESTIONNAIRE Radiation Oncology

PATIENT HEALTH QUESTIONNAIRE Radiation Oncology REVIEWED DATE / INITIALS Safety: Yes No Are you at risk for falls? Do you have a Pacemaker? Females; Is there a possibility you may be pregnant? Allergies: Yes No If YES, please list medication allergies:

More information

DATE OF BIRTH: MELANOMA INTAKE

DATE OF BIRTH: MELANOMA INTAKE MELANOMA INTAKE GENERAL INFORMATION How was your first diagnosed? (Check the diagnosis that describes your condition.) Melanoma Merkel Cell Carcinoma Squamous Cell Carcinoma Basal Cell Carcinoma Other

More information

Essential Shared Care Agreement Drugs for Dementia

Essential Shared Care Agreement Drugs for Dementia Ref No. E052 Please complete the following details: Patient s name, address, date of birth Consultant s contact details (p.3) And send One copy to: 1. the patient s GP 2. put one copy in care plan 3. give

More information

Core Safety Profile. Pharmaceutical form(s)/strength: Immediate release tablets 1 mg, 2 mg, 4 mg and 8 mg (IR) Date of FAR:

Core Safety Profile. Pharmaceutical form(s)/strength: Immediate release tablets 1 mg, 2 mg, 4 mg and 8 mg (IR) Date of FAR: Core Safety Profile Active substance: Doxazosin Pharmaceutical form(s)/strength: Immediate release tablets 1 mg, 2 mg, 4 mg and 8 mg (IR) P - RMS: DK/H/PSUR/0004/002 Date of FAR: 12.12.2011 4.3 Contraindications

More information

Docetaxel + Carboplatin + Trastuzumab

Docetaxel + Carboplatin + Trastuzumab Docetaxel + Carboplatin + Trastuzumab Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient

More information

BC Cancer Protocol Summary for Treatment of Platinum Resistant Epithelial Ovarian Cancer with Bevacizumab and Vinorelbine

BC Cancer Protocol Summary for Treatment of Platinum Resistant Epithelial Ovarian Cancer with Bevacizumab and Vinorelbine BC Cancer Protocol Summary for Treatment of Platinum Resistant Epithelial Ovarian Cancer with Bevacizumab and Vinorelbine Protocol Code Tumour Group Contact Physician UGOOVBEVV Gynecologic Oncology Dr.

More information

NEW PATIENT VISIT QUESTIONNAIRE

NEW PATIENT VISIT QUESTIONNAIRE HeartHealth A Program of the Dalio Institute of Cardiovascular Imaging NEW PATIENT VISIT QUESTIONNAIRE Name: Date of Birth: / / Address: City: State: Zip: Home Phone #: Work Phone #: Cell #: Email: Preferred

More information

Paclitaxel and Trastuzumab Breast Cancer

Paclitaxel and Trastuzumab Breast Cancer Systemic Anti Cancer Treatment Protocol Paclitaxel and Trastuzumab Breast Cancer PROTOCOL REF: MPHAPTRBR (Version No: 1.0) Approved for use in: HER2 positive breast cancer. For adjuvant use in T1 or T2

More information

(7) VITAL SIGNS (8) LEVEL OF CONSCIOUSNESS (9) MENTAL STATUS (10) SPEECH (11) VISION (12) FUNDUS (PAPILLEDEMA)

(7) VITAL SIGNS (8) LEVEL OF CONSCIOUSNESS (9) MENTAL STATUS (10) SPEECH (11) VISION (12) FUNDUS (PAPILLEDEMA) Radiation Therapy Oncology Group Phase II CNS Lymphoma Follow-Up Form RTOG Study No. 1114 Case # Amended Data Yes INSTRUCTIONS: Submit this form as indicated in the protocol. All dates need to be recorded

More information

Inner Balance Acupuncture

Inner Balance Acupuncture Patient Information Inner Balance Acupuncture 274 Southland Drive, Suite 101, Lexington, KY 40503 859-595-2164 www.acupunctureky.com Name: Today s date: Age: Male Female Marital status: Date of Birth:

More information

Caspian Acupuncture -- Health History Form Anita Tayyebi EAMP, LAc. 652 SW 150 th St Burien WA 98166

Caspian Acupuncture -- Health History Form Anita Tayyebi EAMP, LAc. 652 SW 150 th St Burien WA 98166 Frist Name Last: Date Phone (H) (C) (W) E-mail Address City State Zip Age DOB Place of Birth _ Marital/Partnership Status Preferred Gender Pronoun _ Profession Family Physician Telephone # Referred By

More information

BRAVTPCARB. Protocol Code: Breast. Tumour Group: Dr. Karen Gelmon. Contact Physician:

BRAVTPCARB. Protocol Code: Breast. Tumour Group: Dr. Karen Gelmon. Contact Physician: BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer using Trastuzumab (HERCEPTIN), PACLitaxel and CARBOplatin as First-Line Treatment for Advanced Breast Cancer Protocol Code: Tumour

More information

TEXAS VASCULAR ASSOCIATES, P.A. PATIENT CLINICAL INTAKE FORM

TEXAS VASCULAR ASSOCIATES, P.A. PATIENT CLINICAL INTAKE FORM TEXAS VASCULAR ASSOCIATES, P.A. PATIENT CLINICAL INTAKE FORM PATIENT NAME: DATE OF BIRTH: TVA Physician being seen: Date of Visit: PAST MEDICAL HISTORY HEART PROBLEMS NEUROLOGICAL Congestive Heart Failure

More information

MEDICINE SUMMARY. CHLORPROMAZINE HYDROCHLORIDE Layer 1 of 1 ALL REPORT DATES. Febrile neutropenia. Lymphadenopathy. Thrombocythaemia.

MEDICINE SUMMARY. CHLORPROMAZINE HYDROCHLORIDE Layer 1 of 1 ALL REPORT DATES. Febrile neutropenia. Lymphadenopathy. Thrombocythaemia. ALL REPORT DATES Causality Unclear Excluded Total Death Outcome Sole Suspected - Cases Including Medicine - Occurrences of Medicine - Reactions Related to Medicine Blood and lymphatic system disorders

More information

Cisplatin / Paclitaxel Gynaecological Cancer

Cisplatin / Paclitaxel Gynaecological Cancer Systemic Anti Cancer Treatment Protocol Cisplatin / Paclitaxel Gynaecological Cancer PROCTOCOL REF: MPHAGYNCIP (Version No: 1.0) Approved for use in: First line treatment for stage Ib-IV with minimal residual

More information

EC TH s/c Neoadjuvant Breast Cancer

EC TH s/c Neoadjuvant Breast Cancer EC TH s/c Neoadjuvant Breast Cancer Background: Neoadjuvant chemotherapy for inoperable locally advanced, inflammatory breast cancer or to downsize tumour prior to surgery. For patients with HER 2 positive

More information

Database of Adverse Event Notifications - medicines

Database of Adverse Event Notifications - medicines Database of Adverse Event Notifications - medicines You searched for the following 3 medicines between 01/01/2017 01/01/2018: Ferinject 100mg/2mL (Ferric carboxymaltose) Ferinject 500mg/10mL (Ferric carboxymaltose)

More information

Providence Medical Group

Providence Medical Group Providence Medical Group To our valued patients: In order to provide you with our full attention when you come for an appointment, we would like to ask you to be aware of the following guidelines. Insurance

More information

International Trial Relapsed AML 2001/01: Registration

International Trial Relapsed AML 2001/01: Registration Please fax or mail to the appropriate trial office! Appendix I International Trial Relapsed AML 2001/01: Registration Identification number : Surname / Initials: Date of Birth Gender male female dd/mm/yr

More information

PATIENT HEALTH QUESTIONNAIRE Radiation Oncology

PATIENT HEALTH QUESTIONNAIRE Radiation Oncology REVIEWED DATE / INITIALS Safety: Are you at risk for falls? Do you have a Pacemaker? Females; Is there a possibility you may be pregnant? Allergies: If YES, please list medication allergies: Do you have

More information

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.

More information

Patient Treatment Date/time: Diagnosis: Treatment Regimen:

Patient Treatment Date/time: Diagnosis: Treatment Regimen: Name: Address: DOB: HCRN: Consultant: Ward: Assessment: Pre Systematic Anti Cancer Therapy (SACT) Continuation *This assessment is for patients on multiday regimens Patient Treatment Date/time: Diagnosis:

More information

Please list any treatments you have previously had for current illness. (Physical Therapy, Surgery, Radiation, etc.)

Please list any treatments you have previously had for current illness. (Physical Therapy, Surgery, Radiation, etc.) Date: Patient Name: D.O.B Last First M.I History of Present Illness: What is the reason for your visit? Date symptom started? Please list any treatments you have previously had for current illness. (Physical

More information

January 2008 IMPORTANT DRUG WARNING

January 2008 IMPORTANT DRUG WARNING January 2008 IMPORTANT DRUG WARNING Dear Healthcare Professional: Roche would like to advise you of a recent update to the PEGASYS (Peginterferon alfa-2a) and COPEGUS (Ribavirin, USP) package inserts.

More information

Thrombolysis for acute ischaemic stroke Rapid Assessment Protocol NORTHERN IRELAND Regional Protocol (Version 002 July 08)

Thrombolysis for acute ischaemic stroke Rapid Assessment Protocol NORTHERN IRELAND Regional Protocol (Version 002 July 08) Thrombolysis for acute ischaemic stroke Rapid Assessment Protocol NORTHERN IRELAND Regional Protocol (Version 002 July 08) Patient Details Time of onset? Capillary Blood glucose 2.8-22.2 mmol/l? Blood

More information

6.1 CARDIAC DRUGS AGENT FOR CONGESTIVE HEART FAILURE

6.1 CARDIAC DRUGS AGENT FOR CONGESTIVE HEART FAILURE 6.1 CARDIAC DRUGS 6.1.1 AGENT FOR CONGESTIVE HEART FAILURE - 36 - GROUP 6 DIGOXIN Indication: Treatment of congestive heart failure and to slow the ventricular rate in tachyarrhythmias such as atrial fibrillation,

More information

M0BCore Safety Profile. Active substance: Bromazepam Pharmaceutical form(s)/strength: Tablets 6 mg FR/H/PSUR/0066/001 Date of FAR:

M0BCore Safety Profile. Active substance: Bromazepam Pharmaceutical form(s)/strength: Tablets 6 mg FR/H/PSUR/0066/001 Date of FAR: M0BCore Safety Profile Active substance: Bromazepam Pharmaceutical form(s)/strength: Tablets 6 mg P-RMS: FR/H/PSUR/0066/001 Date of FAR: 26.11.2013 4.3 Contraindications Bromazepam must not be administered

More information

M0BCore Safety Profile

M0BCore Safety Profile M0BCore Safety Profile Active substance: Aciclovir Pharmaceutical form(s)/strength: Tablets 200, 400 or 800 mg Dispersible tablets 200, 400 or 800 mg Oral suspensions 200 mg or 400 mg per 5 ml. Freeze

More information

Medication is just part of the management of these illnesses. Other therapies are also helpful; you may wish to discuss these with your prescriber.

Medication is just part of the management of these illnesses. Other therapies are also helpful; you may wish to discuss these with your prescriber. Know Your Medicines Duloxetine The purpose of this leaflet is to give you some general information on duloxetine, and is intended as a guide only. This should be read in conjunction with the official patient

More information

BEVACIZUMAB (AVASTIN ) & Paclitaxel PROTOCOL

BEVACIZUMAB (AVASTIN ) & Paclitaxel PROTOCOL Bevacizumab (Avastin ) & Paclitaxel The treatment of Advanced Breast Cancer DRUG ADMINISTRATION Da Drug Daily Dose Route Diluent & Rate y 250mls Sodium Day 1,15 Bevacizumab 10 mg/kg Infusion Chloride 0.9%*

More information

Joseph S. Weiner, MD, PC Patient History Form

Joseph S. Weiner, MD, PC Patient History Form Date: / / NAME: Last First M. I. Age: Sex: q F q M Birthdate: / / What specific questions or goals do you have for this appointment? Please list the names of other clinicians you have seen for this problem:

More information

Adverse events following immunisation (AEFI) with 2010/2011 seasonal influenza vaccines

Adverse events following immunisation (AEFI) with 2010/2011 seasonal influenza vaccines Adverse events following immunisation (AEFI) with 00/0 seasonal influenza vaccines Netherlands Pharmacovigilance Centre Lareb 8 juli 0 Goudsbloemvallei 7 57 MH s-hertogenbosch www.lareb.nl info@lareb.nl

More information

New Patient History. Name: DOB: Sex: Date: If yes, give the name of the physician who did your evaluation or ordered your tests:

New Patient History. Name: DOB: Sex: Date: If yes, give the name of the physician who did your evaluation or ordered your tests: New Patient History Name: DOB: Sex: Date: Chief Complaint: 1. Give a brief description of the problem you are seeking treatment for today: 2. Have you been evaluated for this problem or had any tests for

More information

Change in Condition: When to report to the MD/NP/PA

Change in Condition: When to report to the MD/NP/PA Change in Condition: When to report to the MD/NP/PA Immediate Notification Any symptom, sign or apparent discomfort that is: Acute or Sudden in onset, and: A Marked Change (i.e. more severe) in relation

More information

THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST. Systemic Anti Cancer Treatment Protocol. EDP + mitotane

THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST. Systemic Anti Cancer Treatment Protocol. EDP + mitotane Systemic Anti Cancer Treatment Protocol EDP + mitotane PROCEDURE REF: MPHAHANEDP (Version No: 1.0) Approved for use in: Symptomatic treatment for advanced (unresectable, metastatic or relapsed) adrenocortical

More information

Broward Oncology Associates, P.A. PATIENT INFORMATION

Broward Oncology Associates, P.A. PATIENT INFORMATION NAME: BIRTHDATE: AGE: LOCAL ADDRESS (Street city state zip): HOME TELEPHONE# CELL # SOCIAL SECURITY #: - - SEX MARITAL STATUS WHAT IS YOUR HT? WHAT IS YOUR WT? EMPLOYER WORK# SPOUSE'S NAME SPOUSE'S EMPLOYER

More information

Change in Condition: When to report to the MD/NP/PA

Change in Condition: When to report to the MD/NP/PA Change in Condition: When to report to the MD/NP/PA Immediate Notification Any symptom, sign or apparent discomfort that is: Acute or Sudden in onset, and: A Marked Change (i.e. more severe) in relation

More information

T- Timing- concise vs. complete and thorough, depending on need of presenter and audience. E- Elicit- ask for feedback- more information needed? Less?

T- Timing- concise vs. complete and thorough, depending on need of presenter and audience. E- Elicit- ask for feedback- more information needed? Less? Review of STAGE presentation framework (from umass.macy.edu, revised Alicia Monroe, MD from 2005 STFM) S- style organization, sequencing adequate to build a case for your diagnosis or a story T- Timing-

More information

Pazopanib in Renal cell carcinoma

Pazopanib in Renal cell carcinoma REGIMEN TITLE: Pazopanib in Renal cell carcinoma Page 1 of 5 Indication: Notes: First line treatment option in advanced renal cell carcinoma Patients who have not received prior cytokine therapy Eastern

More information

Patient Information Last Name: First Name: Middle Initial: Address: City: State: Zip Code:

Patient Information Last Name: First Name: Middle Initial: Address: City: State: Zip Code: Patient Information Last Name: First Name: Middle Initial: Address: City: State: Zip Code: Date of Birth (MM/DD/YY): Social Security #: Sex: Male Female Home Phone #: Mobile Phone #: Email Address: Marital

More information

Have you ever managed patients who have experienced an adverse reaction to transfusion?

Have you ever managed patients who have experienced an adverse reaction to transfusion? Have you ever managed patients who have experienced an adverse reaction to transfusion? A. Yes, often B. Yes, occasionally C. No A. 1 in 30 units? B. 1 in 100? C. 1 in 1000? D. 1 in 10,000? SHOT collects

More information

Cetirizine Proposed Core Safety Profile

Cetirizine Proposed Core Safety Profile Cetirizine Proposed Core Safety Profile Posology and method of administration Elderly subjects: data do not suggest that the dose needs to be reduced in elderly subjects provided that the renal function

More information

Excipients: Each vial of concentrate contains 0.5 ml of ethanol anhydrous (395 mg).

Excipients: Each vial of concentrate contains 0.5 ml of ethanol anhydrous (395 mg). SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT TAXOTERE 20 mg/1 ml concentrate for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of concentrate contains

More information

Summary listing of suspected adverse reactions and events associated with use of Gardasil 01/06/ /12/2015

Summary listing of suspected adverse reactions and events associated with use of Gardasil 01/06/ /12/2015 1 2015-023780 2015-023788 2015-023805 2015-023819 2015-023820 2015-023821 Injection site swelling Transient immobility Abdominal pain Visual acuity reduced Chronic fatigue syndrome Mental disorder Pallor

More information

PERSONAL MEDICAL AND FAMILY HISTORY Please check applicable boxes.

PERSONAL MEDICAL AND FAMILY HISTORY Please check applicable boxes. Name: DOB: PERSONAL MEDICAL AND FAMILY HISTORY Please check applicable boxes. TOBACCO USE: Quit Date Cigarettes Packs/Day Number of years smoked Pipe/Cigar Smokeless Tobacco Electronic or E-cigarette Secondhand

More information

THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST

THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST Outpatient Anti Cancer Treatment Handbook LCV Lomustine, Cisplatin, Vincristine Packer Regimen Repeated every 6 weeks for a maximum of 6 cycles Approved for use in: Medulloblastoma adjuvant therapy Dosage:

More information

Sound View Acupuncture and Chinese Herbs 5410 California Ave SW, #202, Seattle, WA

Sound View Acupuncture and Chinese Herbs 5410 California Ave SW, #202, Seattle, WA Sound View Acupuncture and Chinese Herbs 5410 California Ave SW, #202, Seattle, WA 98136 206.200.3595 Today s date Name Legal name (if different) Phone (primary) (secondary) Address City State Zip Email

More information

BEVACIZUMAB (AVASTIN ) AND XELOX PROTOCOL

BEVACIZUMAB (AVASTIN ) AND XELOX PROTOCOL Bevacizumab (Avastin ) for the first line treatment of advanced colorectal cancer with XELOX DRUG ADMINISTRATION Day Drug Daily Dose Route Diluent & Rate Day 1 Bevacizumab 7.5mg/kg Infusion Day 1 Days

More information